There is a need to clarify whether systemic antibiotic treatment against Pseudomonas aeruginosa in patients with chronic pulmonary diseases is beneficial. We therefore conducted a randomized, good clinical practice (GCP) monitored, controlled trial to determine whether dual systemic antibiotics against Pseudomonas aeruginosa in patients with COPD non-CF bronchiectasis, or asthma, and no current indication for hospital admission, can improve clinical outcomes by reducing antibiotic or prednisolone requiring exacerbations and death.
Protocol (Download)